Remove 2006 Remove Drug Pricing Remove Pharmaceutical Manufacturing
article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. That’s why I refer to them as drug pricing flat earthers (#DPFE). d/b/a Drug Channels Institute.

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. That’s why I refer to them as drug pricing flat earthers (#DPFE). d/b/a Drug Channels Institute.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. But for now, the 2022 data provide fresh inconvenient facts for the drug pricing flat earthers (#DPFE).

article thumbnail

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. But for now, the 2022 data provide fresh inconvenient facts for the drug pricing flat earthers (#DPFE).

article thumbnail

Gross-to-Net Bubble Update: 2023 Pricing Realities at 10 Top Drugmakers

Drug Channels

It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023.

article thumbnail

Five Top Drugmakers Reveal List vs. Net Price Gaps (Plus: The Trouble With Insulin Prices)

Drug Channels

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, drug prices declined—or grew slowly—in 2019. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

article thumbnail

Gross-to-Net Bubble Update: Net Prices Drop (Again) at Six Top Drugmakers

Drug Channels

Time for Drug Channels ' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2020. d/b/a Drug Channels Institute.